Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor

HOUSTON, TX–(Marketwired – January 10, 2018) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced it has expanded the Company’s development pipeline for the treatment of acute myeloid leukemia (“AML”) with an immuno-stimulating STAT3 inhibitor.